arecoline has been researched along with paclitaxel in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Cristofaro, I; Di Bari, M; EspaƱol, AJ; Salem, A; Sales, ME; Sanchez, Y; Tata, AM | 1 |
1 other study(ies) available for arecoline and paclitaxel
Article | Year |
---|---|
The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M2 receptor subtype.
Topics: Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Arecoline; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carbachol; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cholinergic Agonists; Down-Regulation; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Proteins; Neovascularization, Pathologic; Paclitaxel; Receptor, Muscarinic M2; RNA, Small Interfering; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2020 |